01 /Background: the 503A pathway
Section 503A of the Federal Food, Drug, and Cosmetic Act allows licensed compounding pharmacies to prepare individualized medications for specific patients using bulk drug substances. The pathway exists because not every patient need can be met by mass produced FDA registered medicines; sometimes a specific dose, route, or formulation has to be prepared specifically.
For a compounding pharmacy to use a bulk drug substance under 503A, the substance must meet specific criteria: it must be approved by the FDA, or appear in the United States Pharmacopeia or National Formulary, or appear on a list of substances that the FDA has determined are appropriate for compounding.
02 /The bulk drug substances list
To address bulk substances that are not approved drugs and not in the official formularies, the FDA maintains a list called the 503A bulk drug substances list. The list has two categories.
Category 1 includes substances that the FDA Pharmacy Compounding Advisory Committee (PCAC) has reviewed and recommended for inclusion. Compounding pharmacies can use these substances under 503A.
Category 2 includes substances that PCAC has reviewed and recommended against inclusion. The FDA typical interpretation is that compounding pharmacies should not use Category 2 substances. The regulatory effect is that Category 2 substances are effectively unavailable through the legitimate compounding pharmacy pathway.
03 /What Category 2 placement signals
Category 2 placement is not a final determination that a substance is unsafe. It is a finding by PCAC that the safety questions are significant enough that the substance should not be available for compounding without further evaluation.
The grounds for Category 2 placement vary. They include limited published safety data, concerns about manufacturing consistency, concerns about specific adverse events, and questions about the appropriateness of the substance for any clinical use given the data available.
For research peptides, Category 2 placement effectively closes the legitimate compounding pharmacy pathway. The substance can still be synthesized and sold as a research compound, but it cannot be compounded for clinical use.
04 /Peptides on the Category 2 list
Several peptides relevant to the Apothify library have been placed on the Category 2 list following PCAC review. BPC-157 was placed on Category 2 in November 2023. CJC 1295 (the long acting with DAC version), Tesamorelin, and several others have been the subject of PCAC review with various outcomes.
The list is not static. New substances are added, existing substances are reviewed, and the regulatory landscape shifts over time. The Apothify compliance review looks at the current PCAC status as part of the determination of SAFE versus ELEVATED.
05 /How Apothify handles Category 2 entries
Apothify's product gate excludes Category 2 substances from commerce. Any peptide currently on the 503A Category 2 list is classified ELEVATED in the Apothify library and is presented as an encyclopedia entry only.
The encyclopedia listing exists for library completeness; researchers and curious readers can still learn about the compound through the Apothify entry. The cart pathway does not exist; the price is not displayed; the product SKU is not provisioned.
If a Category 2 substance is later moved to Category 1 (which is possible but historically uncommon), the Apothify classification would be re evaluated.
06 /Why this matters beyond compounding pharmacies
The Category 2 designation is specifically about compounding pharmacy use, but the regulatory signal carries weight beyond that narrow context. A Category 2 placement indicates that the FDA has concluded the available safety data does not support clinical use, which informs broader judgments about the appropriate handling of the substance.
For research peptide commerce, the practical effect is that selling a Category 2 substance attracts more regulatory attention than selling a substance with no negative FDA history. Many research peptide suppliers continue to sell Category 2 substances for research use only; the regulatory exposure varies and the landscape continues to evolve.
Apothify chooses the conservative posture: Category 2 substances are encyclopedia only.
07 /How to check current Category 2 status
The FDA publishes the 503A bulk drug substances list on its website. The list is updated periodically. PCAC meeting transcripts are also published and provide the underlying reasoning for each addition.
For peptides specifically, the most commonly affected entries in the Apothify library are BPC-157 (Category 2 as of November 2023) and any peptide that has been the subject of a formal PCAC review.
If you are evaluating a specific peptide for research use, checking current PCAC status is a useful one minute review before placing an order anywhere in the research peptide commerce space.
08 /Adjacent regulatory frameworks
Beyond 503A, several other frameworks affect peptide availability. 503B outsourcing facilities operate under a different set of rules and can use substances on a separate list. The Drug Quality and Security Act of 2013 modernized the broader compounding framework. The DEA controlled substances framework applies to peptides that have psychoactive properties (the endorphin peptides are an example).
For the Apothify library specifically, 503A Category 2 is the most directly relevant framework. Other frameworks affect specific subsets of the library.
09 /What this means for your research decisions
Treat Category 2 placement as a flag to read carefully. The peptide is real and the research literature is real, but the FDA has formally concluded that the substance is not appropriate for clinical compounding.
Treat the absence of Category 2 placement as the absence of a specific FDA concern, not as a positive endorsement. Most peptides in the Apothify library have never been the subject of formal FDA review at all; the absence of a negative determination is not the same as a positive one.
For laboratory research, the regulatory status is one input among several. The published literature, the safety and interactions section, the warning level, and the specific research question all matter alongside the regulatory designation.
